Description Drug for Cancer treatment
ChemicalBook > CAS DataBase List > Bortezomib

Bortezomib

Description Drug for Cancer treatment
Product Name
Bortezomib
CAS No.
179324-69-7
Chemical Name
Bortezomib
Synonyms
VELCADE;dpba;BortezoMib-D8;((R)-3-Methyl-1-((S)-3-phenyl-2-(pyrazine-2-carboxaMido)propanaMido)butyl)boronic acid;MLM341;Bozomi;CS-1886;Radiciol;BortezMib;ortezomib
CBNumber
CB8721789
Molecular Formula
C19H25BN4O4
Formula Weight
384.24
MOL File
179324-69-7.mol
More
Less

Bortezomib Property

Melting point:
122-124°C
Density 
1.214
RTECS 
ED7771666
storage temp. 
Inert atmosphere,Store in freezer, under -20°C
solubility 
Soluble in chloroform, dimethyl sulfoxide, ethanol and methanol.
pka
9.66±0.43(Predicted)
form 
solid
color 
White
Stability:
Hygroscopic and Moisture Sensitive
CAS DataBase Reference
179324-69-7(CAS DataBase Reference)
More
Less

Safety

Risk Statements 
23/24/25-48/23/24/25
Safety Statements 
9-27-36/37-45-60
HazardClass 
6.1
HS Code 
29339900
Hazardous Substances Data
179324-69-7(Hazardous Substances Data)
More
Less

Hazard and Precautionary Statements (GHS)

Symbol(GHS)
Signal word
Danger
Hazard statements

H300Fatal if swallowed

H310Fatal in contact with skin

H330Fatal if inhaled

H372Causes damage to organs through prolonged or repeated exposure

Precautionary statements

P304+P340IF INHALED: Remove victim to fresh air and Keep at rest in a position comfortable for breathing.

P320Specific treatment is urgent (see … on this label).

P330Rinse mouth.

P405Store locked up.

More
Less

N-Bromosuccinimide Price

Sigma-Aldrich
Product number
5.04314
Product name
Bortezomib - CAS 179324-69-7 - Calbiochem
Purity
Bortezomib, CAS 179324-69-7, is a cell-permeable, selective, slowly reversible inhibitor of 20S proteasome β5 ChTL/chymotrypsin- over β1 CL/caspase- and β2 TL/trypsin-like activity.
Packaging
5MG
Price
$129
Updated
2024/03/01
Alfa Aesar
Product number
J60378
Product name
Bortezomib, 99%
Packaging
10mg
Price
$250
Updated
2024/03/01
Alfa Aesar
Product number
J60378
Product name
Bortezomib, 99%
Packaging
25mg
Price
$437
Updated
2024/03/01
Cayman Chemical
Product number
10008822
Product name
Bortezomib
Purity
≥95%
Packaging
1mg
Price
$32
Updated
2024/03/01
Cayman Chemical
Product number
10008822
Product name
Bortezomib
Purity
≥95%
Packaging
5mg
Price
$70
Updated
2024/03/01
More
Less

Bortezomib Chemical Properties,Usage,Production

Description

Bortezomib, a modified dipeptidyl boronic acid, is a therapeutic proteasome inhibitors used for the treatment of cancers. It is indicated for the treatment of relapsed multiple myeloma and mantle cell lymphoma. It is capable of inhibiting the mammalian 26S proteasome, which is important in regulating the intracellular concentration of specific proteins to maintain homeostasis within cells. The disruption of 26S proteasome function disrupts normal cellular homeostasis, leading to cytotoxic effect on various kinds of cancer cells. 

Drug for Cancer treatment

Bortezomib is a drug for treatment of hematopoietic malignancies with the appearance being white or white-like crystalline powder. It is easily soluble in dimethyl sulfoxide, ethanol, but insoluble in aqueous solution. This product is the reversible inhibitor of the mammal cell 26S proteasome chymotrypsin-like activity. 26S proteasome is a large protein complex which can degrade ubiquitin. Ubiquitin proteasome pathway plays an important role in regulation of the intracellular concentration of specific proteins in order to maintain the stability of the intracellular environment. Proteolytic affects intracellular multi-level signalling cascade. The disruption of the normal intracellular environment can lead to cell death while the inhibition of the 26S proteasome can prevent the hydrolysis of specific proteins. In vitro tests have proved bortezomib exhibits cytotoxicity to multiple types of cancer cells. The in vivo models of preclinical tumor have proved that bortezomib is capable of delaying the tumor growth of multiple myeloma which is suitable for the treatment of multiple myeloma.
The above information is edited by the Chemicalbook of Dai Xiongfeng.

Description

Bortezomib, a potent ubiquitin proteasome (26S) inhibitor (Ki=0.6 nM), was launched in the US as a treatment for multiple myeloma. This proteasome is required for the proteolytic degradation of the majority of cellular proteins and is present in all cells. It is required for the control of inflammatory processes, cell cycle regulation and gene expression and is a novel target in cancer treatment. Bortezomib is a N-acyl-pseudodipeptidyl boronic acid and formulated as a mannitol ester. Aldehyde containing peptides are also proteasome inhibitors, but lack chiral stability (racemization) and selectivity against other proteases including cysteine proteases. Replacement of the aldehyde moiety by a boronic acid avoids these shortcomings and provides some measure of selective proteasome inhibition relative to many other serine proteases. It is prepared by coupling the pinanediol ester of leucine boronic acid with N-tert-Bocphenylalanine utilizing O-(1H-benzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium tetrafluoroborate (TBTU) as the coupling agent. The tert-Boc protecting group is then cleaved from the dipeptide and pyrazinecarboxylic acid is coupled to form the terminal amide. Hydrolysis of the boronate ester is accomplished via a two-phase transesterification procedure using isobutyl boronic acid and aqueous extraction. In a study of patients who had received at least two prior therapies and demonstrated disease progression on their most recent therapy, about twenty eight percent showed a response to bortezomib. The response lasted a median time of one year. Another trial in 54 patients with relapsed multiple myeloma showed similar responses. It is dosed intravenously at an exposure of 1.3 mg/m2/dose twice weekly for two weeks followed by a 10-day drug-holiday. At therapeutic doses, the plasma drug levels were reported to drop to near detection limits within minutes of intravenous dosing. Based upon an ex vivo proteasome activity assay using blood cells, the pharmacodynamic half-life ranged from 9 to 15 h in patients with advanced malignancies.

Chemical Properties

Yellow Solid

Originator

Millenium (LeukoSite, Proscript) (US)

Uses

Bortezomib is the first proteasome inhibitor to be approved b the US FDA for multiple myeloma, a blood cancer. A reversible inhibitor of the 26S proteasome-a barrel-shaped multiprotein particle found in the nucleus and cytosol of all eukaryotic cells. T

Uses

A potent, highly selective and reversible inhibitor of the 20S proteasome, Bortezomib is used as an antineoplastic agent, which controls the growth of cancer cells. It is also useful in the treatment of multiple myeloma.

Definition

ChEBI: L-Phenylalaninamide substituted at the amide nitrogen by a 1-(dihydroxyboranyl)-3-methylbutyl group and at Nalpha by a pyrazin-2-ylcarbonyl group. It is a dipeptidyl boronic acid tha reversibly inhibits the 26S proteasome.

brand name

Velcade (Millennium).

General Description

Proteasomes normally function to degrade proteins that areno longer needed by the cell. Such proteins are normallymarked by the addition of ubiquitin, a 76 amino acid proteinthat is added to the -amino group of lysine residues onthe target proteins. The marked proteins are then hydrolyzedby the large barrel-shaped proteasomes to givepeptides of 7 to 8 residues that may be further hydrolyzedand reutilized by the cell. This process serves to regulateprotein levels within the cell, remove defective proteins,and becomes important in maintaining normal signal transduction.Inhibition of the proteasomes results in the buildup of ubiquitylated proteins, which disrupts cell-signalingprocesses and cell growth. The signaling bytranscription factor NF-B (nuclear factor B) appears tobe especially sensitive to bortezomib. NF-B is associatedwith the transcription of antiapoptotic and proliferativegenes but is under the control of IB (inhibitor of NF-B).IB can itself be phosphorylated by IKK (IB kinase),which marks IB for ubiquitylation and destruction allowingNF-B to mediate its antiapoptotic and proliferative effects effects.In the presence of the competitive inhibitor bortezomib(IC50＝0.6 nM), the 26S proteasome is inhibitedand the ubiquitylated IkB is still capable of inhibiting NF-kB, preventing its effects.

Pharmaceutical Applications

Bortezomib belong to the class of drugs called proteasome inhibitors and is licensed in the United States and the United Kingdom for the treatment of multiple myeloma. The drug has been licensed for patients in whom the myeloma has progressed despite prior treatment or where a bone marrow transplant is not possible or was not successful. It is marketed under the name Velcade? or Cytomib?. Velcade is administered via injection and is sold as powder for reconstitution.
Bortezomib was the first drug approved in the new drug class of proteasome inhibitors and boron seems to be its active element. For the mode of action, it is believed that the boron atom binds with high affinity and specificity to the catalytic site of 26S proteasome and inhibits its action. Therapy with Bortezomib can lead to a variety of adverse reactions, including peripheral neuropathy, myelosuppression, renal impairment and gastrointestinal (GI) disturbances together with changes in taste. Nevertheless, the side effects are in most cases less severe than with alternative treatment options such as bone marrow transplantation.

Biochem/physiol Actions

Cell permeable: yes

Clinical Use

Proteasome inhibitor:

Treatment of multiple myeloma for people who have already tried at least 1 prior therapy and have disease progression

Synthesis

Although the synthesis of dipeptidyl boronic acids have appeared on several reports, the synthetic details for bortezomib were not revealed. The synthetic route for the preparation of bortezomib is depicted in the scheme.The pinanediol ester of leucine boronic acid (56)was coupled with N-Boc phenylalanine (57) in the presence of TBTU followed by deprotection of the Boc group to provide 58. N-Acylation of 58 then furnished the dipeptide boronate ester 60. Deprotection of the boronic ester functionality was achieved by bi-phase transfer esterification with isobutyl boronic acid. Bortezomib (VI) was isolated by extractive workup.

target

20S proteasome

Drug interactions

Potentially hazardous interactions with other drugs
Antibacterials: potential reduced efficacy with rifampicin resulting in increased monoclonal IgG λ – avoid.
Antipsychotics: avoid with clozapine, increased risk of agranulocytosis.

Metabolism

In vitro studies with human liver microsomes and human cDNA-expressed cytochrome P450 isozymes indicate that bortezomib is primarily oxidatively metabolised via cytochrome P450 enzymes, 3A4, 2C19, and 1A2. The major metabolic pathway is deboronation to form two deboronated metabolites that subsequently undergo hydroxylation to several metabolites. Deboronated-bortezomib metabolites are inactive as 26S proteasome inhibitors.

storage

+4°C

References

1) Adams et al. (1999), Proteasome inhibitors: a novel class of potent and effective antitumor agents; Cancer Res., 59 2615 2) Williams et al. (2003), Differential effects of the proteasome inhibitor bortezomib on apoptosis and angiogenesis in human prostate tumor xenografts; Mol. Cancer Ther., 2 835 3) Richardson et al. (2003), Bortezomib (PS-341): a novel, first-in-class proteasome inhibitor for the treatment of multiple myeloma and other cancers; Cancer Control, 10 361 4) Herve and Ibrahim (2017), Proteasome inhibitors to alleviate aberrant IKBKAP mRNA splicing and low IKAP/hELP1 synthesis in familial dysautonomia; Neurobiol. Dis., 103 113

Bortezomib Preparation Products And Raw materials

Raw materials

Preparation Products

More
Less

Bortezomib Suppliers

Americas 1 Canada 3 China 575 China Hong Kong 1 Cyprus 1 Czech Republic 1 Estonia 1 Europe 3 Finland 1 France 1 Germany 5 India 104 Israel 2 Italy 3 Japan 1 Jordan 1 Mexico 1 Poland 1 Russia 1 South Korea 2 Spain 1 Switzerland 1 United Arab Emirates 1 United Kingdom 7 United States 59 Global 778
VDM Biochemicals
Tel
0330-2528181
Fax
0330-2528171
Email
sales@vdmbio.com
Country
United States
ProdList
510
Advantage
64
LGM Pharma
Tel
1-(800)-881-8210
Fax
615-250-9817
Email
inquiries@lgmpharma.com
Country
United States
ProdList
2123
Advantage
70
AdooQ BioScience, LLC
Tel
+1 (866) 930-6790
Fax
+1 (866) 333-9607
Email
info@adooq.com
Country
United States
ProdList
2782
Advantage
58
ApexBio Technology LLC
Tel
+1-832-696-8203
Fax
+1-832-641-3177
Email
info@apexbt.com
Country
United States
ProdList
477
Advantage
60
HBCChem, Inc.
Tel
+1-510-219-6317
Fax
+1-650-486-1361
Email
sales@hbcchem.com
Country
United States
ProdList
10648
Advantage
60
ALB Technology Limited
Tel
702-983-3769
Fax
702-983-3769
Email
sales@albtechnology.com
Country
United States
ProdList
2993
Advantage
55
Target molecule Corp.
Tel
857-239-0968
Fax
857-239-8801
Email
service1@targetmol.com
Country
United States
ProdList
2559
Advantage
60
Alabiotech Inc.
Tel
001-619-354-5251
Fax
001-855-855-6087
Email
sales@alabiotech-e.com
Country
United States
ProdList
972
Advantage
60
TargetMol Chemicals Inc.
Tel
+1-781-999-5354 +1-00000000000
Email
marketing@targetmol.com
Country
United States
ProdList
32165
Advantage
58
Alfa Chemistry
Tel
Fax
1-516-927-0118
Email
Info@alfa-chemistry.com
Country
United States
ProdList
24072
Advantage
58
InvivoChem
Tel
+1-708-310-1919 +1-13798911105
Fax
708-557-7486
Email
sales@invivochem.cn
Country
United States
ProdList
6391
Advantage
58
Cckinase, Inc.
Tel
+1 (732)236-3202
Email
sales@cckinase.com
Country
United States
ProdList
2738
Advantage
58
BOC Sciences
Tel
+1-631-485-4226
Fax
1-631-614-7828
Email
inquiry@bocsci.com
Country
United States
ProdList
19553
Advantage
58
Cato Research Chemicals Inc.
Tel
020-81215950 4000-868-328
Email
customer@uwalab.com
Country
United States
ProdList
10404
Advantage
58
Alchem Pharmtech,Inc.
Tel
8485655694
Email
sales@alchempharmtech.com
Country
United States
ProdList
63687
Advantage
58
Aladdin Scientific
Tel
+1-+1(833)-552-7181
Email
sales@aladdinsci.com
Country
United States
ProdList
57505
Advantage
58
Protheragen-ING
Tel
+16313385890
Email
info@protheragen-ing.com
Country
United States
ProdList
3868
Advantage
58
ApexBio Technology
Tel
--
Fax
--
Email
sales@apexbt.com
Country
United States
ProdList
6251
Advantage
58
Thoreau Chem Limited
Tel
--
Fax
--
Email
sales@thoreauchem.com
Country
United States
ProdList
483
Advantage
50
CarboMer, Inc.
Tel
--
Fax
--
Email
sales@carbomer.com
Country
United States
ProdList
4026
Advantage
67
Focus Biomolecules
Tel
--
Fax
--
Email
sales@focusbiomolecules.com
Country
United States
ProdList
1284
Advantage
58
Cayman Chemical Company
Tel
--
Fax
--
Email
cayman@caymanchem.com
Country
United States
ProdList
6213
Advantage
81
APICORE US LLC
Tel
--
Fax
--
Email
support@apicore.com
Country
United States
ProdList
7
Advantage
58
Aozeal Certified Standards (AOCS), Inc.
Tel
--
Fax
--
Email
info@aozeal.com
Country
United States
ProdList
504
Advantage
58
Alichem Inc.
Tel
--
Fax
--
Email
sales@alichem.com
Country
United States
ProdList
6167
Advantage
58
TOPCHEM PHARMACEUTICALS LTD
Tel
--
Fax
--
Email
Vinchem@vinchem.com
Country
United States
ProdList
140
Advantage
58
Selleck Chemicals LLC
Tel
--
Fax
--
Email
sales@selleckchem.com
Country
United States
ProdList
1848
Advantage
58
RTM Pharmaceuticals, L.L.C.
Tel
--
Fax
--
Email
jlevi@rtmpharma.com
Country
United States
ProdList
41
Advantage
58
Kare Bay Biochem Inc.
Tel
--
Fax
--
Email
product@karebaybio.com
Country
United States
ProdList
110
Advantage
58
POLYMED THERAPEUTICS INC
Tel
--
Fax
--
Email
info@polymedt.com
Country
United States
ProdList
14
Advantage
58
Genegobio Inc.
Tel
--
Fax
--
Email
mark@genegobio.com
Country
United States
ProdList
195
Advantage
0
Arasto Pharmaceutical Chemicals Inc.
Tel
--
Fax
--
Email
commercial@arasto.com
Country
United States
ProdList
23
Advantage
30
ACIC Fine Chemicals Inc.
Tel
--
Fax
--
Email
sales@acic.com
Country
United States
ProdList
492
Advantage
48
SST Corporation
Tel
--
Fax
--
Email
info@sst-corp.com
Country
United States
ProdList
237
Advantage
38
OChem Incorporation
Tel
--
Fax
--
Email
sales@ocheminc.com
Country
United States
ProdList
6501
Advantage
60
Aris Pharmaceutical, Inc.
Tel
--
Fax
--
Email
sales@arispharma.com
Country
United States
ProdList
27
Advantage
0
LC Laboratories
Tel
--
Fax
--
Email
custserv@lclabs.com
Country
United States
ProdList
503
Advantage
50
Creative Enzymes
Tel
--
Fax
--
Email
info@creative-enzymes.com
Country
United States
ProdList
6057
Advantage
58
MedChemExpress
Tel
--
Fax
--
Email
sales@medchemexpress.com
Country
United States
ProdList
6398
Advantage
58
Axon Medchem LLC
Tel
--
Fax
--
Email
info@axonmedchem.com
Country
United States
ProdList
763
Advantage
58
Frontier Scientific, Inc.
Tel
--
Fax
--
Email
sales@frontiersci.com
Country
United States
ProdList
6222
Advantage
86
Matrix Scientific
Tel
--
Fax
--
Email
sales@matrixscientific.com
Country
United States
ProdList
6632
Advantage
80
ChemieTek
Tel
--
Fax
--
Email
info@chemietek.com
Country
United States
ProdList
219
Advantage
50
Olinax Inc.
Tel
--
Fax
--
Email
info@olinax.com
Country
United States
ProdList
404
Advantage
50
SynFine Research
Tel
--
Fax
--
Email
research@synfine.com
Country
United States
ProdList
1024
Advantage
68
Focus Synthesis LLC
Tel
--
Fax
--
Email
acd@focussynthesis.com
Country
United States
ProdList
2487
Advantage
61
Selleck Chemicals LLC
Tel
--
Fax
--
Email
info@selleckchem.com
Country
United States
ProdList
824
Advantage
60
LKT Laboratories, Inc.
Tel
--
Fax
--
Email
info@lktlabs.com
Country
United States
ProdList
2164
Advantage
64
Tecoland Corporation
Tel
--
Fax
--
Email
info@tecoland.com
Country
United States
ProdList
275
Advantage
50
Pure Chemistry Scientific Inc
Tel
--
Fax
--
Email
sales@purechems.com
Country
United States
ProdList
2321
Advantage
50
More
Less

View Lastest Price from Bortezomib manufacturers

WUHAN FORTUNA CHEMICAL CO., LTD
Product
Bortezomib 179324-69-7
Price
US $0.00/KG
Min. Order
1KG
Purity
99.0%
Supply Ability
100KG/month
Release date
2021-07-03
BEIJING SJAR TECHNOLOGY DEVELOPMENT CO., LTD.
Product
Bortezomib 179324-69-7
Price
US $0.00/g
Min. Order
1g
Purity
More Than 99%
Supply Ability
100kg/Month
Release date
2024-08-02
BEIJING SJAR TECHNOLOGY DEVELOPMENT CO., LTD.
Product
Bortezomib. 179324-69-7
Price
US $0.00/g
Min. Order
1g
Purity
More Than 99%
Supply Ability
100kg/Month
Release date
2024-11-15

179324-69-7, BortezomibRelated Search:

Isopropyl alcohol PHENYL VALERATE Acetaminophen Kresoxim-methyl Thiophanate-methyl Glucosamine Bensulfuron methyl tert-Butylchlorodiphenylsilane EC 2.6.1.2 Zolmitriptan Propyl butyrate 3,4'-DIAMINODIPHENYLMETHANE Methyl salicylate Propyl gallate Methyl Phenylacetone Methyl bromide n-Butylboronic acid

  • Boronic acid, B-[(1R)-3-Methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(2-pyrazinylcarbonyl)aMino]propyl]aMino]bu
  • MG-341 PS-341
  • BortezoMib Base
  • BortezoMib-D8
  • bortezoMib(other)
  • MLM341
  • BortezoMib R
  • VELCADE(BORTEZOMIB)
  • Boronic acid, B-[(1R)-3-methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(2-pyrazinylcarbonyl)amino]propyl]amino]butyl]-
  • Bortezomib for research
  • Bortezomib ( Velcade, MG-341, PS-341 )
  • (R)-3-methyl-1-((S)-3-phenyl-2-(pyrazine-5-carboxamido)propanamido)butylboronic acid
  • BORTEZOMIB; MG-341; PS-341
  • BortezoMib(Velcade)
  • BortezoMib for res
  • BortezMib
  • 10MG/50MG/1G
  • N-pyrazinoyl-L-phenylalanine-L-boronoleucine
  • ((R)-3-Methyl-1-((S)-3-phenyl-2-(pyrazine-2-carboxaMido)propanaMido)butyl)boronic acid
  • [(1S)-3-Methyl-1-[(2R)-3-phenyl-2-(pyrazin-2-ylforMaMido)propanaMido]butyl]boronic acid
  • Radiciol
  • Bortezomib （Intermediate in China ONLY）
  • CS-1886
  • BortezoMib (PS-341, LDP-341, MLM341)
  • BortezoMib (PS-341)
  • chloro-4-fluoro-phenyl)aMino]-6-nitro-7-[(S)-(tetrahydrofuran-3-yl)oxy]quinazolin
  • N-(2-Pyrazinecarbonyl)-L-phenylalanine-L-leucine boronic anhydride
  • B-[(1R)-3-methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(2-pyrazinylcarbonyl)amino]propyl]amino]butyl]-boronic acid
  • DPBA Bortezomib (PS-341)
  • Bortezomib [(1R)-3-Methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(pyrazinylcarbonyl)amino]propyl]amino]butyl]-boronic acid
  • EZSolution PS-341
  • Bortezomib, >=98%
  • VELCADE
  • dpba
  • BORTEZOMIB
  • [(1r)-3-methyl-1-[[(2s)-1-oxo-3-phenyl-2-[(pyrazinylcarbonyl)amino]propyl]amino]butyl]-boronic acid
  • 3-methyl-1-((S)-3-phenyl-2-(pyrazine-2-carboxamido)propanamido)butylboronic acid
  • Bortezomib for Injection
  • Brotezamide
  • Bortezomib USP/EP/BP
  • ortezomib
  • Bortezomib (10mM in DMSO)
  • bortezomib working std
  • Bortezomib D8Q: What is Bortezomib D8 Q: What is the CAS Number of Bortezomib D8 Q: What is the storage condition of Bortezomib D8 Q: What are the applications of Bortezomib D8
  • BortezomibQ: What is Bortezomib Q: What is the CAS Number of Bortezomib Q: What is the storage condition of Bortezomib Q: What are the applications of Bortezomib
  • Bortezomib Boronic acid, B-[(1R)-3-Methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(2-pyrazinylcarbonyl)aMino]propyl]aMino]bu
  • Bortezomib(Trimeric Boroxine Form)
  • (R) -3-Methyl-1-((S)-3-phenyl-2-(pyrazine-2-carboxamido) propanamido)-butyl boronic acid Bortizomib
  • Bortezomi API
  • Bozomi
  • Nuclear factor-kappaB,Inhibitor,Nuclear factor-κB,Apoptosis,PS 341,PS341,Autophagy,Proteasome,NSC-681239,LDP341,PS-341,inhibit,NF-κB,Bortezomib,LDP-341,NSC681239
  • Bortezomib 99%
  • Bortezomib API
  • Bortzeomib solution (10mM/L)
  • ((R)-3-Methyl-1-((S)-3-phenyl-2-(pyrazine-2-carboxamido)propanamido)butyl)boronic acid , Bortezomib
  • 179324-69-7
  • 79324-69-7
  • C19H25BN4O4